Efficacy of posaconazole in a murine model of central nervous system aspergillosis

被引：49

作者：

Imai, JK

Singh, G

Clemons, KV

Stevens, DA

机构：

[1] Santa Clara Valley Med Ctr, Div Infect Dis, Dept Med, San Jose, CA 95128 USA

[2] Calif Inst Med Res, San Jose, CA 95128 USA

[3] Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 10期

关键词：

D O I：

10.1128/AAC.48.10.4063-4066.2004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Human central nervous system (CNS) aspergillosis has >90% mortality. We compared posaconazole with other antifungals for efficacy against murine CNS aspergillosis. All tested regimens of posaconazole were equivalent to those of amphotericin B and superior in prolonging survival and reducing CFU to those of itraconazole and caspofungin and to vehicle controls. No antifungal regimen effected cure. No toxicity was noted. Overall, posaconazole shows potential for treating CNS aspergillosis.

引用

收藏

页码：4063 / 4066

页数：4

相关论文

共 36 条

[1] Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice [J].

Abruzzo, GK ;

Gill, CJ ;

Flattery, AM ;

Kong, L ;

Leighton, C ;

Smith, JG ;

Pikounis, VB ;

Bartizal, K ;

Rosen, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2310-2318

[2]

[Anonymous], M38A NAT COMM CLIN L

[3] In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates [J].

Arikan, S ;

Lozano-Chiu, M ;

Paetznick, V ;

Rex, JH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :327-330

[4] Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans [J].

Barchiesi, F ;

Schimizzi, AM ;

Caselli, F ;

Giannini, D ;

Camiletti, V ;

Fileni, B ;

Giacometti, A ;

Di Francesco, LF ;

Scalise, G .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (06) :769-773

[5] In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida [J].

Cacciapuoti, A ;

Loebenberg, D ;

Corcoran, E ;

Menzel, F ;

Moss, EL ;

Norris, C ;

Michalski, M ;

Raynor, K ;

Halpern, J ;

Mendrick, C ;

Arnold, B ;

Antonacci, B ;

Parmegiani, R ;

Yarosh-Tomaine, T ;

Miller, GH ;

Hare, RS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2017-2022

[6] Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS [J].

Caillot, D ;

Bassaris, H ;

McGeer, A ;

Arthur, C ;

Prentice, HG ;

Seifert, W ;

De Beule, K .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :E83-E90

[7] Efficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection [J].

Chiller, TM ;

Sobel, RA ;

Luque, JC ;

Clemons, KV ;

Stevens, DA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (02) :813-815

[8] Development of a murine model of cerebral aspergillosis [J].

Chiller, TM ;

Luque, JC ;

Sobel, RA ;

Farrokhshad, K ;

Clemons, KV ;

Stevens, DA .

JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (04) :574-577

[9] In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis [J].

Dannaoui, E ;

Borel, E ;

Persat, F ;

Monier, MF ;

Piens, MA .

JOURNAL OF MEDICAL MICROBIOLOGY, 1999, 48 (12) :1087-1093

[10] Acquired itraconazole resistance in Aspergillus fumigatus [J].

Dannaoui, E ;

Borel, E ;

Monier, MF ;

Piens, MA ;

Picot, S ;

Persat, F .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (03) :333-340

← 1 2 3 4 →